Suzhou Ribo Life Science Co., Ltd. and Boehringer Ingelheim reach the first milestone in joint research and development-Suzhou Ribo Life Science Co., Ltd. Technology Co., Ltd.
Suzhou Ribo Life Science Co., Ltd. Technology Co., Ltd. and its international R&D center Ribocure Pharmaceuticals AB (collectively known as "Suzhou Ribo Life Science Co., Ltd.") are pleased to announce that they have reached the first key milestone agreed in the cooperation agreement with Germany's Boehringer Ingelheim (click here to view the original text of Boehringer Ingelheim's announcement).
On January 3, 2024, Suzhou Ribo Life Science Co., Ltd. and Boehringer Ingelheim announced a major cooperation agreement to jointly develop innovative small nucleic acid therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) (click the link to view details). The cooperation between the two parties has achieved such breakthrough progress less than a year after the project was officially launched, which not only demonstrates Boehringer Ingelheim's professional strength in the field of MASH treatment, but also proves the solidity of Suzhou Ribo Life Science Co., Ltd.'s small nucleic acid technology platform and the team's excellent and efficient international cooperation capabilities. We expect that with the joint efforts of both parties, we will continue to achieve multiple subsequent milestones and provide new treatment options for MASH patients.
About Boehringer Ingelheim
Boehringer Ingelheim is committed to researching breakthrough treatments that transform lives and protect the health of generations to come. As a leading R&D-driven global biopharmaceutical company, the company delivers value through innovation in areas of high unmet medical need. Since its founding in 1885, Boehringer Ingelheim has been an independent, family-owned company with a long-term focus. It has more than 53,000 employees in the human pharmaceuticals and animal health business areas and serves more than 130 regions. For more information visit: www.boehringer-ingelheim.com.
About Suzhou Ribo Life Science Co., Ltd. and Ribo International R&D Center
Suzhou Ribo Life Science Co., Ltd. is an innovative R&D enterprise dedicated to the development of RNA interference (RNAi) drugs. It is a major pioneer and leader in China's small nucleic acid technology and small nucleic acid pharmaceutical industry. Suzhou Ribo Life Science Co., Ltd. benchmarks the innovation frontier of international small nucleic acid technology and is committed to the iterative research and development of small nucleic acid chemical modification and drug delivery technology. It has established an independent and controllable small nucleic acid drug research and development platform with full technology chain integration to support research on small nucleic acid drugs at all stages from early development to industrialization. The company has established a rich product pipeline focusing on cardiometabolic diseases, liver diseases, kidney diseases and rare diseases. The company adheres to differentiated targets and product layout, has an international innovative R&D team, carries out product R&D and commercialization around the world, and strives to bring new drug treatments to patients as soon as possible. See www.ribolia.com for more information. Ruibo International R&D Center is located in Gothenburg, Sweden. It is the company's global clinical development and business development base. It has a professional team with international vision and global clinical development capabilities. The center has built clinical trial bases and laboratories to lead and promote the global clinical trials and commercial development of innovative small nucleic acid drugs. See www.ribocure.com for more information.